-
-
Login
Diabetes UK received £43.8 million in 2025, but only 6½p in every £1 was committed to new research from its core funds. We look at where the rest goes, who sets the priorities, how much influence ordinary fundraisers really have, and why major funders can negotiate very different terms.
Novo Nordisk is adopting the shorter name ‘Novo’ as part of a major global rebrand. Behind the new logo is a wider shift in how one of diabetes’s oldest companies sees healthcare, patients and an increasingly consumer-driven market.
New research analysing almost 47 million CGM readings reveals how often glucose reaches a sensor's measurement limits, how long it can remain there and what that means for the information we see.
